Size-dependent brain distribution of macromolecular drug delivery platform
Summary:
The NCI seeks research co-development partners and/or licensees for a selective polylysine succinylated (PLS) drug delivery platform.
New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer
Summary:
The National Institutes of Health is seeking commercial partners to co-develop and/or license a heterocyclic scaffold for development of therapeutics against Plk1-dependent cancers.
Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Description of Technology:
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction. This promising new therapeutic approach
Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use
Description of Technology:
This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
Human and Improved Murine Monoclonal Antibodies Against CD22
Summary:
Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.
Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection
Summary:
Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis
Summary:
The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis.
Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics
Summary:
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.
Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)
Summary:
NICHD is seeking licensees for development of an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).
Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens
Description of Technology:
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.